GURU.Markets stock price, segment price, and overall market index valuation
The company's share price CLYM
Climb Bio, a biotech company specializing in immunology, is valued in the private market based on the progress of its research programs. The potential post-IPO share price will depend on the results of preclinical and clinical trials of its drugs.
Share prices of companies in the market segment - Pharma immune
Climb Bio Inc. is likely a biotech company focused on developing treatments for immune or inflammatory diseases. We classify it in the "Pharmaceuticals (Immunology)" segment for general classification. The chart below shows the dynamics of this cutting-edge, yet high-risk, medical field.
Broad Market Index - GURU.Markets
Climb Bio is a biotech company developing microbiome-targeted drugs for the treatment of inflammatory and autoimmune diseases. Its innovative approach makes it a component of the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
CLYM - Daily change in the company's share price CLYM
Climb Bio Inc's daily volatility reflects its extreme sensitivity to news in the biotech sector. Change_co for this company is a measure of speculative interest. This metric is important for analyzing risks in the emerging biotech sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Climb Bio Inc is a biotech company. This chart highlights the sector's extreme volatility. Comparison with CLYM's performance, which depends on clinical trial results, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Climb Bio is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization CLYM
Climb Bio Inc's year-to-date performance is a story of developing new treatments for immune diseases. Its 12-month market cap depends entirely on progress in preclinical and early clinical trials, where the company must prove the potential of its scientific platform to create effective and safe drugs.
Annual dynamics of market capitalization of the market segment - Pharma immune
Climb Bio, a private biotech company, likely develops drugs for the treatment of immunological diseases. Its growth depends on success in clinical trials. Its valuation dynamics reflect investors' confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Climb Bio is privately held and not publicly traded. Its market performance cannot be analyzed. As a biotech focused on treating microbiome-related diseases, its value is determined solely by clinical trial results, not economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization CLYM
Climb Bio is an early-stage biotech company, and its value is driven by expectations. Monthly fluctuations reflect progress in preclinical or early clinical trials. Positive scientific data or news of raising funding for the next stage of development are the main catalysts for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the volatile biotech sector. For Climb, a clinical-stage company, it's the backdrop. Its movements show how successes and failures in clinical trials, as well as M&A activity, have impacted investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotechnology, especially in a cutting-edge field like the microbiome, is a world ruled by scientific data, not market cycles. The chart below shows the overall sentiment. Does Climb Bio Inc. exist in its own universe, where a successful research outcome can spark explosive growth despite any market downturn?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization CLYM
Shares of Climb Bio, a biotech company focused on treating immune diseases, reflect weekly progress in this complex field. The price movement is a response to preclinical and clinical trial data that could offer hope to patients with serious illnesses.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Climb Bio is a pharmaceutical company focused on immunology. Like many biotech companies, its value depends on progress in drug development. This chart will help investors separate the wheat from the chaff: are Climb Bio's weekly stock fluctuations driven by company news or are they a general investor reaction to industry-wide events?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Climb Bio is a biotech company whose value depends on clinical trial results. Shares in this sector often move independently of the market. This chart will help you understand whether Climb Bio shares follow the broader market or whether news about its developments creates a completely independent trajectory.
Market capitalization of the company, segment and market as a whole
CLYM - Market capitalization of the company CLYM
As a private biotech, Climb Bio's market capitalization would be a story about science and investor faith. Its chart would reflect progress in developing treatments for microbiome-related diseases. Its valuation dynamics would be a series of jumps driven by news of preclinical and clinical successes, not financial metrics.
CLYM - Share of the company's market capitalization CLYM within the market segment - Pharma immune
Climb Bio is a biopharmaceutical company focused on treating immune and inflammatory diseases. Its market capitalization reflects investor confidence in the company's scientific platform and development pipeline. The chart shows how the market views its potential relative to other players in the field.
Market capitalization of the market segment - Pharma immune
Climb Bio is another biotech company working in the field of immunology. The chart below shows the overall market capitalization of this knowledge-intensive sector. Its volatile dynamics reflect the hopes and disappointments that accompany the long journey of developing new drugs to treat complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Climb Bio is a biotech company working in the field of immunology. The valuation of such early-stage companies reflects investors' faith in the scientific hypothesis and the team. Their volatility on the overall chart reflects the long and risky journey from an idea to a potential life-changing cure.
Book value capitalization of the company, segment and market as a whole
CLYM - Book value capitalization of the company CLYM
Climb Bio's balance sheet is its capital, which is dedicated to developing innovative therapies for the treatment of autoimmune and inflammatory diseases by targeting the microbiome. This is a real, scientific foundation for a new approach to medicine. How is this young biotech asset shaping up? The chart below shows its initial dynamics.
CLYM - Share of the company's book capitalization CLYM within the market segment - Pharma immune
Climb Bio, a biopharmaceutical company, utilizes research laboratories to develop its immune-diseases drugs. The chart shows the share of these knowledge-intensive tangible assets in the sector, reflecting the physical foundation upon which its scientific research is built.
Market segment balance sheet capitalization - Pharma immune
Climb Bio is a biotech company focused on immunology research. Its main assets are patents, not product lines. A book value chart will show how "light" the company is in terms of physical capital.
Book value of all companies included in the broad market index - GURU.Markets
Climb Bio Inc. develops new treatments for autoimmune diseases. The company's book value is represented by its research laboratories, scientific equipment, and capital for preclinical studies. The chart shows the material base on which innovative approaches to immune system modulation are built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - CLYM
Climb Bio's balance sheet is capital for research. Its market price is the pure faith of investors in its scientific approach to treating inflammatory diseases. The chart shows a "hope factor," which can be enormous but is extremely volatile depending on news from the lab.
Market to book capitalization ratio in a market segment - Pharma immune
Climb Bio is a biopharmaceutical company, likely focused on immunology. Like other early-stage biotechs, its value is determined by the potential of its scientific developments. The chart shows investors' bets on the future success of its research, rather than on its current assets.
Market to book capitalization ratio for the market as a whole
Climb Bio is another biotech company working in the field of immunology. Its value is determined solely by its scientific potential and clinical trial prospects. This chart shows the overall market valuation, but how do investors evaluate scientific hypotheses that could lead to a breakthrough or end in failure?
Debts of the company, segment and market as a whole
CLYM - Company debts CLYM
Climb Bio, like many early-stage biotech companies, is entirely dependent on external funding. This schedule likely reflects its survival strategy: raising capital to conduct preclinical and early clinical trials. This is a high-risk investment in a scientific hypothesis.
Market segment debts - Pharma immune
Climb Bio is another biotech company focused on immunology. Developing new treatments for immune disorders is a lengthy and capital-intensive process. This chart shows the company's financial structure and how it secures the resources to conduct multi-year clinical trials in this complex field.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio CLYM
Climb Bio is a pharmaceutical company focused on immunology. This chart is vital for understanding its financial health. It shows how reliant the company is on borrowed funds to conduct expensive clinical trials. This dynamic reflects a race against time: will the company be able to develop a product before running out of funds?
Market segment debt to market segment book capitalization - Pharma immune
Climb Bio Inc. is likely a biopharmaceutical company focused on immunology. This chart shows the collective debt load in the immunopharmaceutical sector. It helps understand how the industry as a whole finances its long-term and risky clinical research, and how the financial model of the young company Climb Bio fits into this context.
Debt to book value of all companies in the market
Climb Bio is a biopharmaceutical company focused on immunology. Its activities involve lengthy and expensive research, typically financed with equity rather than debt. This chart, showing the overall market leverage, illustrates the difference between the biotech venture capital model and traditional industries, which are heavily indebted.
P/E of the company, segment and market as a whole
P/E - CLYM
This chart for Climb Bio, a biopharmaceutical company, shows how investors value its research and development. As with many companies in this industry at the research stage, this metric can be very high or irrelevant. It reflects not current profits, but rather the hopes for the future commercial success of its immunology drugs.
P/E of the market segment - Pharma immune
Treating immune diseases, which Climb Bio is likely pursuing, is a promising area. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that such companies are valued as research projects, and their value depends on the success of clinical trials and the potential of their drugs to become a new standard of care.
P/E of the market as a whole
Climb Bio Inc. is likely a biotech company, possibly focused on immunology or infectious diseases. The success of such companies depends on clinical trial data. This chart, showing investors' overall risk appetite, is an indicator of the market's willingness to fund early-stage research.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company CLYM
Climb Bio — (Note: Likely private or very young company). For a biopharmaceutical company in the immunology field, this chart would reflect speculative expectations, entirely dependent on the success of preclinical and clinical studies, as well as the potential size of the addressable market for its future drugs.
%20P%2FE%20CLYM&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-CLYM&v=1772463476493 "Chart of the company's future (projected) P/E CLYM")
Future (projected) P/E of the market segment - Pharma immune
Climb Bio is a biotech company focused on immunology. This chart shows average profitability expectations for the sector. It allows investors to assess how the company's scientific approach and the potential of its developments compare to other players seeking to develop new treatments for immune diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772463476493 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Climb Bio Inc. is a biotech company focused on developing treatments for microbiome-related diseases, particularly inflammatory conditions. This chart shows investors' risk appetite. For a company operating in a relatively new field of medicine, it reflects the market's willingness to fund innovative treatment approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772463476495 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit CLYM
Climb Bio Inc. is an early-stage biotechnology company focused on immunological diseases. The financial metrics presented here reflect research and preclinical development expenses. This chart illustrates the initial stage of the drug discovery process, where all resources are focused on testing the scientific hypothesis.
Profit of companies in the market segment - Pharma immune
Climb Bio Inc. is likely a biotech company focused on immunology. Such companies often work on treating autoimmune diseases or developing vaccines. This chart illustrates how research into the immune system can lead to breakthrough drugs and significantly impact the profitability of the entire pharmaceutical industry.
Overall market profit
Climb Bio is an early-stage biotech company focused on immunology. For companies like this, without revenue, access to venture capital is key. The growth phase, which typically coincides with revenue growth on this graph, increases investors' risk appetite and their willingness to fund long-term research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company CLYM
Climb Bio is a biotech company developing therapeutic approaches for the treatment of immune diseases. The profit (or loss) projections in this chart reflect the long and capital-intensive research and development process. Analysts assess the scientific potential of the company's platform and the likelihood of success in future clinical trials.
%20profit%20of%20the%20company%20CLYM&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-CLYM&v=1772463476499 "Graph of future (projected) profit of the company CLYM")
Future (predicted) profit of companies in the market segment - Pharma immune
Climb Bio is a biotech company likely focused on developing therapies that modulate the immune system for the treatment of various diseases. This chart shows the revenue forecast for the immune pharmaceutical sector, providing context for assessing the scientific and commercial potential of the company's research and development efforts relative to the industry as a whole.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772463476500 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Climb Bio is a biopharmaceutical company. Like other companies in this sector, its success depends less on the current economic cycle than on research results and the ability to attract capital. This graph, reflecting overall investor sentiment, influences the availability of funding for long-term research projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772463476501 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - CLYM
Climb Bio is a biotech company focused on developing treatments for immune diseases. This chart reflects investor expectations for its scientific developments. Estimating its potential future revenue is a bet on the success of its approaches to treating complex autoimmune and inflammatory conditions.
P/S market segment - Pharma immune
Climb Bio is a biotech company focused on developing therapies targeting the microbiome—the community of microorganisms living within humans—to combat immune diseases. This chart shows the industry average price-to-sales ratio. It reflects investor expectations for this cutting-edge research and the company's development potential.
P/S of the market as a whole
Climb Bio is a biopharmaceutical company focused on developing therapeutics for microbiome-related diseases. This is a cutting-edge and rapidly growing field in medicine. This chart helps understand how the market values science-intensive companies whose revenue potential is based on completely new approaches to treating diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company CLYM
Climb Bio is a biotech company, likely in its early stages, focused on immunology. This chart shows its valuation relative to future, hypothetical sales. It indicates investor confidence in its scientific platform and the potential for developing treatments for immune-related diseases.
%20P%2FS%20CLYM&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-CLYM&v=1772463476507 "The graph of the company's future (projected) P/S CLYM")
Future (projected) P/S of the market segment - Pharma immune
Climb Bio is likely a biotech company developing immunology drugs. Estimates of future revenue for such companies depend almost entirely on the success of their research and clinical trials. This metric reflects investor expectations for its R&D relative to other immunology startups.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772463476508 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Climb Bio is a biotech company focused on immunology. Its future depends on the success of its research and clinical trials. This graph of overall market expectations for CLYM is not a direct driver. The company's value is determined by its scientific potential and ability to develop effective treatments, not by the current economic climate.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772463476510 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales CLYM
This chart illustrates the financial trajectory of a biotech company in the development stage. For Climb Bio, which focuses on treating autoimmune and infectious diseases, it reflects revenue from grants and partnerships, not sales, which is typical for companies in preclinical development.
Sales of companies in the market segment - Pharma immune
Climb Bio Inc. is a biotech company likely focused on immunology. Being in the early stages, it is contributing to the future of the sector. This chart reflects current revenue in the immunotherapy field, and a potential breakthrough by Climb Bio in treating autoimmune diseases could radically change the landscape and size of this market.
Overall market sales
Climb Bio is a biotechnology company developing treatments for autoimmune diseases. Its research is focused on creating a new generation of drugs. The success of such companies shapes the future of healthcare, one of the largest and most innovative sectors, which has a profound impact on the entire modern economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company CLYM
Climb Bio is a biotech company focused on developing treatments for autoimmune and inflammatory diseases by targeting the microbiome. Future sales projections are dependent on the success of its groundbreaking clinical trials. This graph reflects expectations for the development of one of the most promising areas of modern medicine.
%20sales%20of%20the%20company%20CLYM&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-CLYM&v=1772463476519 "Schedule of future (projected) sales of the company CLYM")
Future (projected) sales of companies in the market segment - Pharma immune
Climb Bio Inc. is a biotech company focused on immunology. This forecast for the entire immune pharmaceutical sector reflects overall investment sentiment and scientific trends. This chart provides context, allowing one to assess how the company's specific developments may stand out against the general expectations in this complex field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772463476520 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Climb Bio Inc. is likely a biotech company focused on immunology. Like other early-stage companies in this sector, its success is determined by scientific data and research results. The overall economic dynamics shown here do not directly impact its performance, but are important for attracting investment and for investors' assessment of the entire sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772463476526 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality CLYM
Climb Bio is a biotech company developing microbiome-based therapies for inflammatory diseases. Being in the early stages of research, it incurs significant R&D expenditures. This chart illustrates the level of investment in its scientific platform, which is typical for innovative companies in this industry.
Market segment marginality - Pharma immune
Climb Bio Inc. is a biotechnology company focused on developing treatments for immune diseases. Its financial metrics currently reflect intensive research and development. This chart helps evaluate the company's operational structure and level of investment in research compared to other immunology firms.
Market marginality as a whole
Climb Bio Inc. is a biotech company developing treatments for immune diseases. This chart shows average returns. Compared to this, Climb Bio is another example of a company whose value stems from its intellectual property and R&D potential, not its current profits. Its financials reflect R&D expenses.
Employees in the company, segment and market as a whole
Number of employees in the company CLYM
Climb Bio is an early-stage biotech company developing treatments for autoimmune diseases. Its extremely small staff consists of a core group of scientists. Any significant increase in this graph would indicate significant progress, including successful funding and expansion of the research program.
Share of the company's employees CLYM within the market segment - Pharma immune
Climb Bio is likely a private or early-stage biotech company focused on immunology. This graph would show its starting position. It would reflect a small but highly concentrated group of immunology scientists working on a specific disease or therapeutic platform, forming the core of the future company.
Number of employees in the market segment - Pharma immune
Climb Bio Inc. is a biotech company focused on immunology. This chart for the cutting-edge biopharma sector shows that growth here is driven not by mass production, but by intellectual capital. The number of scientists at such companies reflects progress in understanding the immune system and developing new classes of drugs.
Number of employees in the market as a whole
Climb Bio Inc. is an early-stage biotech company focused on immunology. For companies like this, headcount is not a relevant indicator. Their staff consists of a small group of highly qualified scientists, and expansion depends entirely on research results and successful raising of venture capital for the next stages of development.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company CLYM (CLYM)
Climb Bio is a biopharmaceutical company working at the forefront of immunology. For companies like these, science is the primary driver of value. This chart shows how investors value intellectual capital. The high market value per scientist reflects the enormous potential of their discoveries to create new treatments for complex diseases.
%20of%20the%20company%20CLYM%20(CLYM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-CLYM-CLYM&v=1772463476538 "Chart of market capitalization per employee (in thousands of dollars) of the company CLYM (CLYM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Climb Bio is a biopharmaceutical company focused on immunology. Its market capitalization reflects market expectations for scientific developments, not the size of its current staff. This chart shows the premium the market is willing to pay for the intellectual capital of each employee working on potentially breakthrough treatments.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772463476539 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Climb Bio is a biopharmaceutical company focused on immunology. In this field, scientific breakthroughs can lead to the development of cures for a wide range of diseases. This chart reflects the high valuation per employee typical in biotech, where a company's value is determined by the potential of its scientific platform rather than by its current operations.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772463476540 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company CLYM (CLYM)
Climb Bio (Climb Innovative Therapies) is, as its name suggests, a biotech R&D company focused on immunology. Like most preclinical biotechs, its staff consists of scientists. This metric is likely negative. It reflects the company's "burn rate"—how much capital the company spends on each researcher per year to develop its therapeutic platforms.
%20Chart%20CLYM%20(CLYM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-CLYM-CLYM&v=1772463476540 "Company Profit Per Employee (in thousands of dollars) Chart CLYM (CLYM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Climb Bio is another biotech company focused on immunology. As with other R&D firms, this graph serves as a long-term benchmark. At the research stage, profitability per employee is not the key factor. What matters is scientific productivity: whether the CLYM team can create a drug that will ultimately generate financial returns above the industry average.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772463476542 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Climb Bio is another biotech company working in the field of immunology. As with other R&D companies in the preclinical or early clinical stages, this metric does not reflect current profitability. It is an indicator of the cost of maintaining a team of scientists. This trend shows how the company manages personnel costs as it advances its developments to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772463476543 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee CLYM (CLYM)
Climb Bio, a biotech company focused on immunology, is in the research phase. This graph reflects its current status as an R&D company with no commercial sales. It serves as a baseline. In the future, following potential commercialization or partnerships, this metric will demonstrate the economic value created by its scientific team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-CLYM-CLYM&v=1772463476545 "Sales chart per company employee CLYM (CLYM)")
Sales per employee in the market segment - Pharma immune
Climb Bio is a biotech company focused on developing treatments for microbiome-related diseases. This is a cutting-edge field of medicine. While this metric is likely low at the R&D stage, it reflects how effectively their research team generates revenue (e.g., from partnerships) per employee.
Sales per employee for the market as a whole
Climb Bio is a biotech company apparently in the early stages of developing treatments for immune diseases. This chart shows revenue per employee. For a company focused on R&D and without a product on the market, this figure is expected to be zero or very low. He emphasizes that all resources and personnel are dedicated to scientific research.
Short shares by company, segment and market as a whole
Shares shorted by company CLYM (CLYM)
Climb Bio (likely CLIMB Therapeutics) is a biotech company developing treatments for immune diseases. This chart shows bearish bets. As with any clinical-stage company, bears are betting that its drug candidates will fail clinical trials and fail to demonstrate sufficient efficacy or safety, which is a key risk in biotech.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-CLYM-CLYM&v=1772463476549 "Short Shares Chart for the Company CLYM (CLYM)")
Shares shorted by market segment - Pharma immune
Climb Bio is a biotech company specializing in immune diseases. This chart shows overall short positions across the biotech sector. The high short interest in the industry reflects general investor skepticism about the sector, possibly due to recent clinical trial setbacks or concerns about R&D funding in the current economic environment.
Shares shorted by the overall market
Climb Bio (CLYM) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing that CLYM will be unable to raise funds to continue R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator CLYM (CLYM)
Climb Bio (CLYM) is a clinical-stage biotech. The stock is extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect setbacks, funding concerns, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-CLYM-CLYM&v=1772463476551 "RSI 14 indicator chart for the company's stock CLYM (CLYM)")
RSI 14 Market Segment - Pharma immune
Climb Bio (CLYM) is a biotech company developing antibodies to treat immune and inflammatory diseases. The RSI_14_Seg for "Pharma immune" shows whether the entire biotech segment is overheated. The chart helps us understand whether CLYM's volatility is a reaction to their trials or simply the general hype in the sector.
RSI 14 for the overall market
Climb Bio (CLYM) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CLYM (CLYM)
Climb Bio is an early-stage biotech developing drugs to treat immune diseases. This chart shows the average analyst price target. For such a company, the target price is a collective speculative bet on the success of their scientific platform and the potential for preclinical development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CLYM-CLYM&v=1772463476554 "A chart showing analyst consensus forecasts for the expected stock price. CLYM (CLYM)")
The difference between the consensus estimate and the actual stock price CLYM (CLYM)
Climb Bio (CLYM) is a biotech R&D company specializing in immunology. This chart clearly demonstrates the "hope gap" inherent in biotech. It shows the difference between the current, speculative share price and the analyst consensus price target, which assumes the potential success of their clinical trials and a treatment breakthrough.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CLYM-CLYM&v=1772463476555 "A chart showing the difference between the consensus forecast and the actual stock price. CLYM (CLYM)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Climb Bio is a biotech startup developing microbiome-based therapies for autoimmune diseases. It's a dark horse betting on a breakthrough in this emerging field. This chart shows analysts' overall expectations for the immune pharma sector, reflecting whether experts believe such R&D platforms will be commercially successful.
Analysts' consensus forecast for the overall market share price
Climb Bio (CLYM) is a biotech company developing microbiome-targeted therapies to combat autoimmune diseases. This chart shows overall risk appetite. For Climb Bio, operating in a new and risky field, overall market optimism is critical to raising the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index CLYM
Climb Bio is a clinical-stage biotech focused on developing a new class of drugs to treat immune diseases. It's a binary risk business: all or nothing. This chart is a pure indicator of faith in their R&D. It doesn't reflect current sales (they don't have any), but rather a speculative assessment of their scientific progress, clinical trial data, and their chances of regulatory approval.
AKIMA Market Segment Index - Pharma immune
Climb Bio (Climb Therapeutics) is at the forefront of science, developing microbiome-based therapies for immune diseases. In biotech, R&D must be balanced with operational efficiency. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Climb Bio, which is developing breakthrough technology, compares to the industry average.
The AKIM Index for the overall market
Climb Bio is a biotech company focused on developing treatments for immune-inflammatory diseases. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop, which is critical for funding such speculative clinical-stage scientific projects.
